Sign in
Back
Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia
Journal article   Open access  Peer reviewed

Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia

Niyaz Ahmad, Rizwan Ahmad, Farhan Jalees Ahmad, Wasim Ahmad, Md Aftab Alam, Mohd Amir and Abuzer Ali
Saudi journal of biological sciences, Vol.27(1), pp.500-517
01/01/2020
DOI: https://doi.org/10.1016/j.sjbs.2019.11.008
PMCID: PMC6933235
PMID: 31889876

Abstract

ANOVA., analysis of variance AUC, area under curve BA, bioavailability Cerebral ischemia CLSM, confocal laser scanning microscopy Cmax, maximum plasma concentration CS, chitosan ESI, electrospray ionization HQC, high quality control Kel, elimination rate constant LLE, liquid–liquid extraction LLOQ QC, lower limit of quantification for quality control LLOQ, lower limit of quantification LOD, lower limit of detection LOQ, lower limit of quantitation LQC, low quality control MCAO, middle cerebral artery occlusion MCAO-oxidative stress MQC, middle quality control MS, ultra high performance liquid chromatography mass spectroscopy and mass spectroscopy MS-pharmacokinetic Mucoadhesive-chitosan-based-nanoemulsion-gel Naringenin NE, nanoemulsion NRG, naringenin PDI, polydispersity index PK, pharmacokinetic Q-TOF, quadrupole time of flight SEM, scanning electron microscope TBARS, thiobarbituric acid reactive substances TEM, transmission electron microscope Tmax, time to Cmax t½, half-life UHPLC-MS
url
https://doi.org/10.1016/j.sjbs.2019.11.008View
Published (Version of record) Open

Metrics

1 Record Views
Article has an altmetric score of 6

See more details

105 readers on Mendeley

Details